BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rossi JF, Négrier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P, Berns B. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010;103:1154-62. [PMID: 20808314 DOI: 10.1038/sj.bjc.6605872] [Cited by in Crossref: 130] [Cited by in F6Publishing: 119] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Masjedi A, Hashemi V, Hojjat-farsangi M, Ghalamfarsa G, Azizi G, Yousefi M, Jadidi-niaragh F. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomedicine & Pharmacotherapy 2018;108:1415-24. [DOI: 10.1016/j.biopha.2018.09.177] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 15.3] [Reference Citation Analysis]
2 Patra MC, Shah M, Choi S. Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases. Semin Cancer Biol 2020;64:61-82. [PMID: 31054927 DOI: 10.1016/j.semcancer.2019.05.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
3 Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, Yao Y. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141:125-139. [PMID: 24076269 DOI: 10.1016/j.pharmthera.2013.09.004] [Cited by in Crossref: 271] [Cited by in F6Publishing: 265] [Article Influence: 30.1] [Reference Citation Analysis]
4 Mayer CL, Xie L, Bandekar R, Qi M, van de Velde H, Reddy M, Qin X, Davis HM, Puchalski TA. Dose selection of siltuximab for multicentric Castleman's disease. Cancer Chemother Pharmacol 2015;75:1037-45. [PMID: 25784388 DOI: 10.1007/s00280-015-2720-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bhutani D, Vaishampayan UN. Monoclonal antibodies in oncology therapeutics: present and future indications. Expert Opin Biol Ther 2013;13:269-82. [PMID: 23286740 DOI: 10.1517/14712598.2012.758705] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
6 Wang Y, Zhang Y. Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis. Clin Transl Oncol 2020;22:835-43. [DOI: 10.1007/s12094-019-02192-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Harmer D, Falank C, Reagan MR. Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma.Front Endocrinol (Lausanne). 2018;9:788. [PMID: 30671025 DOI: 10.3389/fendo.2018.00788] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 17.3] [Reference Citation Analysis]
8 Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904-910. [PMID: 22651903 DOI: 10.1016/j.ctrv.2012.04.007] [Cited by in Crossref: 401] [Cited by in F6Publishing: 402] [Article Influence: 40.1] [Reference Citation Analysis]
9 Thilakasiri PS, Dmello RS, Nero TL, Parker MW, Ernst M, Chand AL. Repurposing of drugs as STAT3 inhibitors for cancer therapy. Semin Cancer Biol. 2019;. [PMID: 31711994 DOI: 10.1016/j.semcancer.2019.09.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
10 Morel J, Tournadre A, Sellam J, Bouhnik Y, Cornec D, Devauchelle-Pensec V, Dieudé P, Goupille P, Kluger N, Lazaro E, Le Goff B, de Lédinghen V, Lequerré T, Nocturne G, Seror R, Truchetet ME, Verhoeven F, Pham T, Richez C. Practical Management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine 2021;88:105221. [PMID: 34183155 DOI: 10.1016/j.jbspin.2021.105221] [Reference Citation Analysis]
11 Thomas SK, Suvorov A, Noens L, Rukavitsin O, Fay J, Wu KL, Zimmerman TM, van de Velde H, Bandekar R, Puchalski TA, Qi M, Uhlar C, Samoylova OS. Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer Chemother Pharmacol 2014;73:35-42. [PMID: 24149943 DOI: 10.1007/s00280-013-2314-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
12 Metcalfe RD, Putoczki TL, Griffin MDW. Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11. Front Immunol 2020;11:1424. [PMID: 32765502 DOI: 10.3389/fimmu.2020.01424] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
13 Chen R, Chen B. Siltuximab (CNTO 328): a promising option for human malignancies. Drug Des Devel Ther 2015;9:3455-8. [PMID: 26170629 DOI: 10.2147/DDDT.S86438] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
14 Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014;3:e27048. [PMID: 24605265 DOI: 10.4161/onci.27048] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 59.0] [Reference Citation Analysis]
15 Baay M, Brouwer A, Pauwels P, Peeters M, Lardon F. Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol. 2011;2011:565187. [PMID: 22162712 DOI: 10.1155/2011/565187] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 7.4] [Reference Citation Analysis]
16 Waldner MJ, Foersch S, Neurath MF. Interleukin-6--a key regulator of colorectal cancer development. Int J Biol Sci 2012;8:1248-53. [PMID: 23136553 DOI: 10.7150/ijbs.4614] [Cited by in Crossref: 194] [Cited by in F6Publishing: 183] [Article Influence: 19.4] [Reference Citation Analysis]
17 Accogli T, Bruchard M, Végran F. Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. Cancers (Basel) 2021;13:373. [PMID: 33498483 DOI: 10.3390/cancers13030373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Market M, Tennakoon G, Auer RC. Postoperative Natural Killer Cell Dysfunction: The Prime Suspect in the Case of Metastasis Following Curative Cancer Surgery. Int J Mol Sci 2021;22:11378. [PMID: 34768810 DOI: 10.3390/ijms222111378] [Reference Citation Analysis]
19 Setrerrahmane S, Xu H. Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer 2017;16:153. [PMID: 28927416 DOI: 10.1186/s12943-017-0721-9] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 17.0] [Reference Citation Analysis]
20 Marech I, Leporini C, Ammendola M, Porcelli M, Gadaleta CD, Russo E, De Sarro G, Ranieri G. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment. Cancer Lett 2016;380:216-26. [PMID: 26238184 DOI: 10.1016/j.canlet.2015.07.028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
21 Hashimoto H, Ueda R, Narumi K, Heike Y, Yoshida T, Aoki K. Type I IFN gene delivery suppresses regulatory T cells within tumors. Cancer Gene Ther 2014;21:532-41. [DOI: 10.1038/cgt.2014.60] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
22 Sawa-Wejksza K, Kandefer-Szerszeń M. Tumor-Associated Macrophages as Target for Antitumor Therapy. Arch Immunol Ther Exp (Warsz) 2018;66:97-111. [PMID: 28660349 DOI: 10.1007/s00005-017-0480-8] [Cited by in Crossref: 73] [Cited by in F6Publishing: 79] [Article Influence: 14.6] [Reference Citation Analysis]
23 Nikanjam M, Yang J, Capparelli EV. Population pharmacokinetics of siltuximab: impact of disease state. Cancer Chemother Pharmacol 2019;84:993-1001. [PMID: 31482226 DOI: 10.1007/s00280-019-03939-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
24 Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology 2015;4:e985940. [PMID: 25949870 DOI: 10.4161/2162402X.2014.985940] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
25 Shi X, Shiao SL. The role of macrophage phenotype in regulating the response to radiation therapy. Transl Res 2018;191:64-80. [PMID: 29175267 DOI: 10.1016/j.trsl.2017.11.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
26 Weber R, Groth C, Lasser S, Arkhypov I, Petrova V, Altevogt P, Utikal J, Umansky V. IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cell Immunol 2021;359:104254. [PMID: 33296753 DOI: 10.1016/j.cellimm.2020.104254] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
27 Gyamfi J, Eom M, Koo JS, Choi J. Multifaceted Roles of Interleukin-6 in Adipocyte-Breast Cancer Cell Interaction. Transl Oncol 2018;11:275-85. [PMID: 29413760 DOI: 10.1016/j.tranon.2017.12.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 9.3] [Reference Citation Analysis]
28 Ataie-Kachoie P, Pourgholami MH, Morris DL. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev 2013;24:163-73. [PMID: 23107589 DOI: 10.1016/j.cytogfr.2012.09.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 5.5] [Reference Citation Analysis]
29 Öcal O, Kupčinskas J, Morkunas E, Amthauer H, Schütte K, Malfertheiner P, Klümpen HJ, Sengel C, Benckert J, Seidensticker R, Sangro B, Wildgruber M, Pech M, Bartenstein P, Ricke J, Seidensticker M. Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization. EJNMMI Res 2021;11:51. [PMID: 34080071 DOI: 10.1186/s13550-021-00791-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Servais FA, Kirchmeyer M, Hamdorf M, Minoungou NWE, Rose-John S, Kreis S, Haan C, Behrmann I. Modulation of the IL-6-Signaling Pathway in Liver Cells by miRNAs Targeting gp130, JAK1, and/or STAT3. Mol Ther Nucleic Acids 2019;16:419-33. [PMID: 31026677 DOI: 10.1016/j.omtn.2019.03.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
31 Auezova R, Ivanova N, Akshulakov S, Zhetpisbaev B, Kozhakhmetova A, Ryskeldiyev N, Mustafin K, Teltayev D, Auezova L. Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients. Cancer Manag Res 2019;11:3227-36. [PMID: 31114362 DOI: 10.2147/CMAR.S195754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
32 Madaro L, Passafaro M, Sala D, Etxaniz U, Lugarini F, Proietti D, Alfonsi MV, Nicoletti C, Gatto S, De Bardi M, Rojas-García R, Giordani L, Marinelli S, Pagliarini V, Sette C, Sacco A, Puri PL. Denervation-activated STAT3-IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis. Nat Cell Biol 2018;20:917-27. [PMID: 30050118 DOI: 10.1038/s41556-018-0151-y] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 18.3] [Reference Citation Analysis]
33 Fang H, Declerck YA. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res. 2013;73:4965-4977. [PMID: 23913938 DOI: 10.1158/0008-5472.can-13-0661] [Cited by in Crossref: 164] [Cited by in F6Publishing: 91] [Article Influence: 18.2] [Reference Citation Analysis]
34 Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell. 2018;33:965-983. [PMID: 29657130 DOI: 10.1016/j.ccell.2018.03.002] [Cited by in Crossref: 131] [Cited by in F6Publishing: 134] [Article Influence: 32.8] [Reference Citation Analysis]
35 Kamińska K, Czarnecka AM, Escudier B, Lian F, Szczylik C. Interleukin-6 as an emerging regulator of renal cell cancer. Urol Oncol 2015;33:476-85. [PMID: 26296264 DOI: 10.1016/j.urolonc.2015.07.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
36 Shi H, Li J, Fu D. Process of hepatic metastasis from pancreatic cancer: biology with clinical significance. J Cancer Res Clin Oncol 2016;142:1137-61. [PMID: 26250876 DOI: 10.1007/s00432-015-2024-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
37 Gudbrandsdottir G, Aarstad HH, Bostad L, Hjelle KM, Aarstad HJ, Bruserud Ø, Tvedt THA, Beisland C. Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC). Cancer Immunol Immunother 2021;70:19-30. [PMID: 32621022 DOI: 10.1007/s00262-020-02655-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Ramesh V, Selvarasu K, Pandian J, Myilsamy S, Shanmugasundaram C, Ganesan K. NFκB activation demarcates a subset of hepatocellular carcinoma patients for targeted therapy. Cell Oncol 2016;39:523-36. [DOI: 10.1007/s13402-016-0294-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
39 van Duijneveldt G, Griffin MDW, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clin Sci (Lond) 2020;134:2091-115. [PMID: 32808663 DOI: 10.1042/CS20191211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
40 Osuala KO, Sameni M, Shah S, Aggarwal N, Simonait ML, Franco OE, Hong Y, Hayward SW, Behbod F, Mattingly RR, Sloane BF. Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. BMC Cancer 2015;15:584. [PMID: 26268945 DOI: 10.1186/s12885-015-1576-3] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 8.1] [Reference Citation Analysis]
41 Macaulay R, Akbar AN, Henson SM. The role of the T cell in age-related inflammation. Age (Dordr). 2013;35:563-572. [PMID: 22252437 DOI: 10.1007/s11357-012-9381-2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 7.7] [Reference Citation Analysis]
42 Liu Q, Yu S, Li A, Xu H, Han X, Wu K. Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment. Tumour Biol 2017;39:1010428317712445. [PMID: 28639898 DOI: 10.1177/1010428317712445] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
43 Baranyai Z, Jósa V, Tóth A, Szilasi Z, Tihanyi B, Zaránd A, Harsanyi L, Szállási Z. Paraneoplastic thrombocytosis in gastrointestinal cancer. Platelets 2016;27:269-75. [PMID: 27136385 DOI: 10.3109/09537104.2016.1170112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
44 Zhao X, Guo W, Zou L, Hu B. FBXO2 modulates STAT3 signaling to regulate proliferation and tumorigenicity of osteosarcoma cells. Cancer Cell Int 2020;20:245. [PMID: 32549792 DOI: 10.1186/s12935-020-01326-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Paniri A, Akhavan-Niaki H. Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation. Life Sci 2020;257:118114. [PMID: 32693241 DOI: 10.1016/j.lfs.2020.118114] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
46 Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology. 2012;1:28-37. [PMID: 22720209 DOI: 10.4161/onci.1.1.17938] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 75.0] [Reference Citation Analysis]
47 Knutson KL, Karyampudi L, Lamichhane P, Preston C. Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev 2015;34:53-74. [PMID: 25544369 DOI: 10.1007/s10555-014-9540-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
48 Bhatia S, Monkman J, Toh AKL, Nagaraj SH, Thompson EW. Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring. Biochem J 2017;474:3269-306. [PMID: 28931648 DOI: 10.1042/BCJ20160782] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
49 Unverzagt S, Moldenhauer I, Nothacker M, Roßmeißl D, Hadjinicolaou AV, Peinemann F, Greco F, Seliger B. Immunotherapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev 2017;5:CD011673. [PMID: 28504837 DOI: 10.1002/14651858.CD011673.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
50 Lin RJ, Afshar-Kharghan V, Schafer AI. Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. Blood 2014;124:184-7. [PMID: 24868077 DOI: 10.1182/blood-2014-03-562538] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 9.0] [Reference Citation Analysis]
51 Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 2013;161:357-66. [PMID: 23432640 DOI: 10.1111/bjh.12266] [Cited by in Crossref: 109] [Cited by in F6Publishing: 132] [Article Influence: 12.1] [Reference Citation Analysis]
52 Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185. [PMID: 24901008 DOI: 10.1155/2014/149185] [Cited by in Crossref: 715] [Cited by in F6Publishing: 748] [Article Influence: 89.4] [Reference Citation Analysis]
53 Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer 2021;21:481-99. [PMID: 34083781 DOI: 10.1038/s41568-021-00363-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
54 Morgenstern DA, Anderson J. Inflammation: What role in pediatric cancer?: Inflammation and Pediatric Cancer. Pediatr Blood Cancer 2012;58:659-64. [DOI: 10.1002/pbc.24008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
55 Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA. TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. Cytokine 2017;89:127-35. [DOI: 10.1016/j.cyto.2016.01.021] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 14.8] [Reference Citation Analysis]
56 Di Lorenzo G, De Placido S, Pagliuca M, Ferro M, Lucarelli G, Rossetti S, Bosso D, Puglia L, Pignataro P, Ascione I, De Cobelli O, Caraglia M, Aieta M, Terracciano D, Facchini G, Buonerba C, Sonpavde G. The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. Expert Opin Biol Ther 2016;16:1387-401. [PMID: 27463642 DOI: 10.1080/14712598.2016.1216964] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
57 Ibrahim ML, Lu C, Klement JD, Redd PS, Yang D, Smith AD, Liu K. Expression profiles and function of IL6 in polymorphonuclear myeloid-derived suppressor cells. Cancer Immunol Immunother 2020;69:2233-45. [PMID: 32488308 DOI: 10.1007/s00262-020-02620-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
58 Yuzhalin AE, Kutikhin AG. IL-6 Family and Cancer. Interleukins in Cancer Biology. Elsevier; 2015. pp. 117-46. [DOI: 10.1016/b978-0-12-801121-8.00005-1] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
59 Erstad DJ, Cusack JC. Targeting the NF-κB Pathway in Cancer Therapy. Surgical Oncology Clinics of North America 2013;22:705-46. [DOI: 10.1016/j.soc.2013.06.011] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
60 Kitamura H, Ohno Y, Toyoshima Y, Ohtake J, Homma S, Kawamura H, Takahashi N, Taketomi A. Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci. 2017;108:1947-1952. [PMID: 28749573 DOI: 10.1111/cas.13332] [Cited by in Crossref: 93] [Cited by in F6Publishing: 96] [Article Influence: 18.6] [Reference Citation Analysis]
61 Menderes G, Schwab CL, Black J, Santin AD. The Role of the Immune System in Ovarian Cancer and Implications on Therapy. Expert Rev Clin Immunol 2016;12:681-95. [PMID: 26821930 DOI: 10.1586/1744666X.2016.1147957] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12:584-596. [PMID: 26122183 DOI: 10.1038/nrclinonc.2015.105] [Cited by in Crossref: 466] [Cited by in F6Publishing: 465] [Article Influence: 66.6] [Reference Citation Analysis]
63 Zhang X, Wang W, Mize GJ, Takayama TK, True LD, Vessella RL. Protease-activated receptor 2 signaling upregulates angiogenic growth factors in renal cell carcinoma. Exp Mol Pathol 2013;94:91-7. [PMID: 22960271 DOI: 10.1016/j.yexmp.2012.08.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
64 Krishnamurthy S, Warner KA, Dong Z, Imai A, Nör C, Ward BB, Helman JI, Taichman RS, Bellile EL, McCauley LK, Polverini PJ, Prince ME, Wicha MS, Nör JE. Endothelial interleukin-6 defines the tumorigenic potential of primary human cancer stem cells. Stem Cells 2014;32:2845-57. [PMID: 25078284 DOI: 10.1002/stem.1793] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 8.6] [Reference Citation Analysis]
65 Yang F, He Z, Duan H, Zhang D, Li J, Yang H, Dorsey JF, Zou W, Nabavizadeh SA, Bagley SJ, Abdullah K, Brem S, Zhang L, Xu X, Byrne KT, Vonderheide RH, Gong Y, Fan Y. Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Nat Commun 2021;12:3424. [PMID: 34103524 DOI: 10.1038/s41467-021-23832-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Oren O, Neilan TG, Fradley MG, Bhatt DL. Cardiovascular Safety Assessment in Cancer Drug Development. J Am Heart Assoc 2021;10:e024033. [PMID: 34913360 DOI: 10.1161/JAHA.121.024033] [Reference Citation Analysis]
67 Kuczma M, Ding ZC, Zhou G. Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells. Crit Rev Immunol 2016;36:179-91. [PMID: 27910767 DOI: 10.1615/CritRevImmunol.2016017507] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
68 Bauman JE, Ferris RL. Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer 2014;120:624-32. [PMID: 24222079 DOI: 10.1002/cncr.28380] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
69 Martins GR, Gelaleti GB, Moschetta MG, Maschio-Signorini LB, Zuccari DA. Proinflammatory and Anti-Inflammatory Cytokines Mediated by NF-κB Factor as Prognostic Markers in Mammary Tumors. Mediators Inflamm 2016;2016:9512743. [PMID: 26989335 DOI: 10.1155/2016/9512743] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
70 Porta C, Paglino C, Imarisio I, Ganini C, Sacchi L, Quaglini S, Giunta V, De Amici M. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology 2013;84:115-22. [PMID: 23154434 DOI: 10.1159/000342099] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
71 Hugo HJ, Lebret S, Tomaskovic-Crook E, Ahmed N, Blick T, Newgreen DF, Thompson EW, Ackland ML. Contribution of Fibroblast and Mast Cell (Afferent) and Tumor (Efferent) IL-6 Effects within the Tumor Microenvironment. Cancer Microenviron 2012;5:83-93. [PMID: 22314376 DOI: 10.1007/s12307-012-0098-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
72 Umezu T, Imanishi S, Yoshizawa S, Kawana C, Ohyashiki JH, Ohyashiki K. Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion. Blood Adv 2019;3:3228-40. [PMID: 31698453 DOI: 10.1182/bloodadvances.2019000403] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
73 Wu Y, Liu Y, Dong Y, Vadgama J. Diabetes-associated dysregulated cytokines and cancer. Integr Cancer Sci Ther 2016;3:370-8. [PMID: 29930868 DOI: 10.15761/ICST.1000173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
74 Porta C, Pedrazzoli P, Paglino C. Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab. Immunotherapy 2011;3:487-90. [PMID: 21463189 DOI: 10.2217/imt.11.19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
75 Pal SK, Williams S, Josephson DY, Carmichael C, Vogelzang NJ, Quinn DI. Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther 2012;11:526-37. [PMID: 22351744 DOI: 10.1158/1535-7163.MCT-11-0806] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
76 Li Z, Riesenberg B, Metelli A, Li A, Wu BX. The Role of Platelets in Tumor Growth, Metastasis, and Immune Evasion. Platelets. Elsevier; 2019. pp. 547-61. [DOI: 10.1016/b978-0-12-813456-6.00030-8] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
77 Elewa U, Sanchez-niño MD, Martin-cleary C, Fernandez-fernandez B, Egido J, Ortiz A. Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled. Int Urol Nephrol 2012;44:1731-44. [DOI: 10.1007/s11255-012-0271-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
78 Tsukamoto H, Fujieda K, Senju S, Ikeda T, Oshiumi H, Nishimura Y. Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity. Cancer Sci 2018;109:523-30. [PMID: 29090850 DOI: 10.1111/cas.13433] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 9.6] [Reference Citation Analysis]
79 Heo TH, Wahler J, Suh N. Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer. Oncotarget 2016;7:15460-73. [PMID: 26840088 DOI: 10.18632/oncotarget.7102] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 12.6] [Reference Citation Analysis]
80 Mochizuki D, Adams A, Warner KA, Zhang Z, Pearson AT, Misawa K, McLean SA, Wolf GT, Nör JE. Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma. Oncotarget 2015;6:22822-35. [PMID: 26287605 DOI: 10.18632/oncotarget.4477] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
81 Ironside AJ, Jones JL. Stromal characteristics may hold the key to mammographic density: the evidence to date. Oncotarget 2016;7:31550-62. [PMID: 26784251 DOI: 10.18632/oncotarget.6912] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
82 Jung HY, Fattet L, Yang J. Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis. Clin Cancer Res. 2015;21:962-968. [PMID: 25107915 DOI: 10.1158/1078-0432.ccr-13-3173] [Cited by in Crossref: 169] [Cited by in F6Publishing: 110] [Article Influence: 21.1] [Reference Citation Analysis]
83 Avalle L, Raggi L, Monteleone E, Savino A, Viavattene D, Statello L, Camperi A, Stabile SA, Salemme V, De Marzo N, Marino F, Guglielmi C, Lobascio A, Zanini C, Forni M, Incarnato D, Defilippi P, Oliviero S, Poli V. STAT3 induces breast cancer growth via ANGPTL4, MMP13 and STC1 secretion by cancer associated fibroblasts. Oncogene 2022. [PMID: 35042959 DOI: 10.1038/s41388-021-02172-y] [Reference Citation Analysis]
84 Cai W, Chen QY, Dang LH, Luesch H. Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors. ACS Med Chem Lett 2017;8:1007-12. [PMID: 29057042 DOI: 10.1021/acsmedchemlett.7b00192] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
85 Klarenbeek A, Blanchetot C, Schragel G, Sadi AS, Ongenae N, Hemrika W, Wijdenes J, Spinelli S, Desmyter A, Cambillau C, Hultberg A, Kretz-Rommel A, Dreier T, De Haard HJ, Roovers RC. Combining somatic mutations present in different in vivo affinity-matured antibodies isolated from immunized Lama glama yields ultra-potent antibody therapeutics. Protein Eng Des Sel 2016;29:123-33. [PMID: 26945588 DOI: 10.1093/protein/gzw003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
86 Kaelin WG. Molecular Biology of Kidney Cancer. In: Lara PN, Jonasch E, editors. Kidney Cancer. Cham: Springer International Publishing; 2015. pp. 31-57. [DOI: 10.1007/978-3-319-17903-2_3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25:198-213. [PMID: 25540894 DOI: 10.1016/j.tcb.2014.11.006] [Cited by in Crossref: 354] [Cited by in F6Publishing: 330] [Article Influence: 44.3] [Reference Citation Analysis]
88 Xiao H, Bid HK, Chen X, Wu X, Wei J, Bian Y, Zhao C, Li H, Li C, Lin J. Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy. PLoS One 2017;12:e0180297. [PMID: 28672024 DOI: 10.1371/journal.pone.0180297] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
89 Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234-248. [PMID: 29405201 DOI: 10.1038/nrclinonc.2018.8] [Cited by in Crossref: 667] [Cited by in F6Publishing: 689] [Article Influence: 166.8] [Reference Citation Analysis]
90 Noori MS, O'Brien JD, Champa ZJ, Deosarkar SP, Lanier OL, Qi C, Burdick MM, Schwartz FL, Bergmeier SC, McCall KD, Goetz DJ. Phenylmethimazole and a thiazole derivative of phenylmethimazole inhibit IL-6 expression by triple negative breast cancer cells. Eur J Pharmacol 2017;803:130-7. [PMID: 28343970 DOI: 10.1016/j.ejphar.2017.03.049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
91 Ho L, Luo S, Lai J. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers. Biochemical Pharmacology 2015;97:16-26. [DOI: 10.1016/j.bcp.2015.06.009] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 5.9] [Reference Citation Analysis]
92 Li S, Priceman SJ, Xin H, Zhang W, Deng J, Liu Y, Huang J, Zhu W, Chen M, Hu W. Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma. PLoS One. 2013;8:e81657. [PMID: 24324713 DOI: 10.1371/journal.pone.0081657] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
93 Geiger JL, Grandis JR, Bauman JE. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol 2016;56:84-92. [PMID: 26733183 DOI: 10.1016/j.oraloncology.2015.11.022] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 11.4] [Reference Citation Analysis]
94 Charbonneau B, Goode EL, Kalli KR, Knutson KL, Derycke MS. The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol 2013;33:137-64. [PMID: 23582060 DOI: 10.1615/critrevimmunol.2013006813] [Cited by in Crossref: 36] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
95 Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013;144:829-40. [PMID: 23295441 DOI: 10.1053/j.gastro.2013.01.001] [Cited by in Crossref: 275] [Cited by in F6Publishing: 294] [Article Influence: 30.6] [Reference Citation Analysis]
96 Dominguez C, David JM, Palena C. Epithelial-mesenchymal transition and inflammation at the site of the primary tumor. Semin Cancer Biol 2017;47:177-84. [PMID: 28823497 DOI: 10.1016/j.semcancer.2017.08.002] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 13.4] [Reference Citation Analysis]
97 Morgan EL, Macdonald A. Manipulation of JAK/STAT Signalling by High-Risk HPVs: Potential Therapeutic Targets for HPV-Associated Malignancies. Viruses 2020;12:E977. [PMID: 32899142 DOI: 10.3390/v12090977] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
98 Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC. Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev. 2013;39:89-96. [PMID: 22858249 DOI: 10.1016/j.ctrv.2012.07.003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 5.9] [Reference Citation Analysis]
99 Davis CC, Shah KS, Lechowicz MJ. Clinical Development of Siltuximab. Curr Oncol Rep 2015;17. [DOI: 10.1007/s11912-015-0453-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
100 Hirota M, Murakami I, Ishikawa Y, Suzuki T, Sumida S, Ibaragi S, Kasai H, Horai N, Drolet DW, Gupta S, Janjic N, Schneider DJ. Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys. Nucleic Acid Ther 2016;26:10-9. [PMID: 26579954 DOI: 10.1089/nat.2015.0567] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
101 Pan D, Xu L, Liu H, Zhang W, Liu W, Liu Y, Fu Q, Xu J. High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. Cancer Sci 2015;106:592-7. [PMID: 25702890 DOI: 10.1111/cas.12638] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
102 Yeung YT, McDonald KL, Grewal T, Munoz L. Interleukins in glioblastoma pathophysiology: implications for therapy. Br J Pharmacol 2013;168:591-606. [PMID: 23062197 DOI: 10.1111/bph.12008] [Cited by in Crossref: 111] [Cited by in F6Publishing: 104] [Article Influence: 12.3] [Reference Citation Analysis]
103 Tawara K, Oxford JT, Jorcyk CL. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res. 2011;3:177-189. [PMID: 21625400 DOI: 10.2147/cmr.s18101] [Cited by in Crossref: 14] [Cited by in F6Publishing: 65] [Article Influence: 1.3] [Reference Citation Analysis]
104 Wang J, Liu J, Chang Q, Yang B, Li S, Gu C. The association between preoperative serum interleukin-6 levels and postoperative prognosis in patients with T2 gallbladder cancer. J Surg Oncol 2018;117:1672-8. [PMID: 29723410 DOI: 10.1002/jso.25085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
105 Han J, Xi Q, Meng Q, Liu J, Zhang Y, Han Y, Zhuang Q, Jiang Y, Ding Q, Wu G. Interleukin-6 promotes tumor progression in colitis-associated colorectal cancer through HIF-1α regulation. Oncol Lett 2016;12:4665-70. [PMID: 28105173 DOI: 10.3892/ol.2016.5227] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
106 Taher MY, Davies DM, Maher J. The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. Biochem Soc Trans 2018;46:1449-62. [PMID: 30467123 DOI: 10.1042/BST20180136] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
107 Vainer N, Dehlendorff C, Johansen JS. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget. 2018;9:29820-29841. [PMID: 30038723 DOI: 10.18632/oncotarget.25661] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 13.0] [Reference Citation Analysis]
108 Wang Y, Fu D, Chen Y, Su J, Wang Y, Li X, Zhai W, Niu Y, Yue D, Geng H. G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas. Cell Death Dis 2018;9:501. [PMID: 29717134 DOI: 10.1038/s41419-018-0504-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
109 Manji A, Brana I, Amir E, Tomlinson G, Tannock IF, Bedard PL, Oza A, Siu LL, Razak AR. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J Clin Oncol 2013;31:4260-7. [PMID: 24127441 DOI: 10.1200/JCO.2012.47.4957] [Cited by in Crossref: 60] [Cited by in F6Publishing: 27] [Article Influence: 6.7] [Reference Citation Analysis]
110 Shinko D, Diakos CI, Clarke SJ, Charles KA. Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine. Clin Pharmacol Ther 2017;102:599-610. [PMID: 28699186 DOI: 10.1002/cpt.789] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
111 Ye C, Qi L, Wang J, Zheng S. COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. Front Med (Lausanne) 2021;8:606755. [PMID: 33855032 DOI: 10.3389/fmed.2021.606755] [Reference Citation Analysis]
112 Wang J, Zhou P, Han Y, Zhang H. Platelet transfusion for cancer secondary thrombocytopenia: Platelet and cancer cell interaction. Transl Oncol 2021;14:101022. [PMID: 33545547 DOI: 10.1016/j.tranon.2021.101022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
113 Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019;50:1007-1023. [PMID: 30995492 DOI: 10.1016/j.immuni.2019.03.026] [Cited by in Crossref: 219] [Cited by in F6Publishing: 219] [Article Influence: 73.0] [Reference Citation Analysis]
114 Widjaja AA, Chothani SP, Cook SA. Different roles of interleukin 6 and interleukin 11 in the liver: implications for therapy. Hum Vaccin Immunother 2020;16:2357-62. [PMID: 32530750 DOI: 10.1080/21645515.2020.1761203] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
115 Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA, Reddy M, Cornfeld M, Eisenberger M. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 2013;31:669-76. [DOI: 10.1007/s10637-012-9857-z] [Cited by in Crossref: 46] [Cited by in F6Publishing: 66] [Article Influence: 4.6] [Reference Citation Analysis]
116 Middleton K, Jones J, Lwin Z, Coward JI. Interleukin-6: an angiogenic target in solid tumours. Crit Rev Oncol Hematol. 2014;89:129-139. [PMID: 24029605 DOI: 10.1016/j.critrevonc.2013.08.004] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 9.4] [Reference Citation Analysis]
117 Li L, Kaelin WG Jr. New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am 2011;25:667-86. [PMID: 21763962 DOI: 10.1016/j.hoc.2011.04.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
118 Förnvik K, Maddahi A, Liljedahl E, Osther K, Salford LG, Redebrandt HN. What is the role of CRP in glioblastoma? Cancer Treat Res Commun 2021;26:100293. [PMID: 33385735 DOI: 10.1016/j.ctarc.2020.100293] [Reference Citation Analysis]
119 Chang Q, Daly L, Bromberg J. The IL-6 feed-forward loop: a driver of tumorigenesis. Semin Immunol 2014;26:48-53. [PMID: 24613573 DOI: 10.1016/j.smim.2014.01.007] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 6.6] [Reference Citation Analysis]
120 Zhang KW, Wang D, Cai H, Cao MQ, Zhang YY, Zhuang PY, Shen J. IL‑6 plays a crucial role in epithelial‑mesenchymal transition and pro‑metastasis induced by sorafenib in liver cancer. Oncol Rep 2021;45:1105-17. [PMID: 33432366 DOI: 10.3892/or.2021.7926] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Kasturirangan S, Rainey GJ, Xu L, Wang X, Portnoff A, Chen T, Fazenbaker C, Zhong H, Bee J, Zeng Z, Jenne C, Wu H, Gao C. Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody. J Biol Chem 2017;292:4361-70. [PMID: 28100773 DOI: 10.1074/jbc.M116.770628] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
122 Babu A, Lachmann H, Pickett T, Boddana P, Ludeman L. Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literature. CEN Case Rep 2014;3:68-74. [PMID: 28509249 DOI: 10.1007/s13730-013-0088-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]